Notably, the interim data from a Phase I/II clinical trial goes on to suggest that mRNA-3927, which happens to be an investigational mRNA therapy from Moderna, can very well be a promising treatment when it comes to propionic acidaemia.
A 70% reduction in terms of risk of metabolic decompensation events had been reported by eight participants across the 12-month pretreatment period, as per the trial results published in Nature.
They are excited to share the first published clinical data by way of using an mRNA therapy for intracellular protein replacement, stated Moderna’s Senior Vice President as well as Head of Development, Therapeutics, and Oncology, Dr. Kyle Holen.
A novel mRNA therapy
mRNA-3927 happens to be a novel lipid nanoparticle- LNP and is an encapsulated dual investigational mRNA therapy. By encoding for the PCC enzyme. It happens to have the potential to replace missing or dysfunctional enzymes, stated the pharmaceutical giant.
Propionic acidaemia is indeed rare and is an inherited metabolic disorder that goes on to result from the body’s inability to go ahead and process specific parts of proteins as well as lipids because of a specific enzyme deficiency. For people with propionic acidaemia, harmful levels of toxic metabolites can build up in the body and can as well lead to metabolic decompensation events as well as multisystemic complexities. These interim data go on to indicate early signs of potential clinical benefit by way of having mRNA-3927 and significantly also demonstrate that mRNA-3927 happens to have an infrequent treatment, limiting the side effects. Dr. Holen said that he is particularly proud of such kind of results given that there happen to be at present no therapeutic treatments that are approved for patients with this disease.
It is well to be noted that the company’s ongoing global Phase I/II clinical trial evaluated the safety, pharmacodynamics, and pharmacokinetics of the IV-administered treatment in participants aged one year and above. Study data happened to be presented at the 2023 American Society of Gene & Cell Therapy- ASGCT Yearly Meeting.
The fact is that as of the latest data cutoff at May 2023 end, more than 15 person-years of therapy were administered.
Moderna confirmed that additional patient enrollment when it comes to dose expansion phase of the study will go on to further assess the efficacy, safety, and pharmacodynamic activity of mRNA-3927.
Apparently, in the week ending March 30, 2024, Moderna went on to share promising data for its next-generation COVID-19 vaccine.
